Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Other Non-Current Liabilities data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 6.92% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 6.92% YoY), and the FY2025 full-year result was $1.1 million, down 7.1% from the prior year.
• Other Non-Current Liabilities was little changed at $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q4 2023 to a low of $37000.0 in Q3 2022.
• A 5-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 4951.35% in 2023 and tumbled 61.14% in 2024, its largest moves.
• Tracing RCKT's Other Non-Current Liabilities over 5 years: stood at $2.6 million in 2022, then advanced by 13.14% to $2.9 million in 2023, then plunged by 61.14% to $1.1 million in 2024, then fell by 7.1% to $1.1 million in 2025, then climbed by 0.19% to $1.1 million in 2026.
• Business Quant data shows RCKT's Other Non-Current Liabilities at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.